Tradestie Institutional Equity Comparison Engine

BIIB vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BIIB Overall Edge

BIIB Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biogen Inc. Common Stock (BIIB) driven by superior Valuation, Growth & Margin, Options & Structure while MRNA counters with relative strength in Momentum & Technical. Fundamentally, BIIB trades at 15.6x Forward P/E with 23.5% operating margin (+10.6% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, BIIB sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BIIB
BIIB 15.6x vs MRNA 23.0x Fwd P/E
Growth & Margin Winner BIIB
Op Margin 23.5% vs -80.8% ยท YoY +10.6% vs +29.2%
Momentum & Technical Winner MRNA
1Y +53.4% vs +765.2% ยท 52W Pos 92% vs 75%
Options & Structure Winner BIIB
CONSOLIDATION (6th %ile IV) vs CONSOLIDATION (30th %ile IV)
BIIB NASDAQ
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
1M Return +8.63%
1Y Return +53.41%
Forward P/E 15.6x
Unified AI Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$215.96
-3.32% 1D
Market Cap $93.6B
1M Return -0.94%
1Y Return +765.2%
Forward P/E 23.0x
Unified AI Score
46.8 / 100 HOLD
Tech 41.0 Fund 50.0 Flow 67.0 Mom 41.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BIIB +53.41% MRNA +765.2% Spread: +711.79 pp (MRNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BIIB Revenue MRNA Revenue BIIB Op. Margin MRNA Op. Margin Margin Edge
FY2018 $13.4B $140M 43.8% -306.0% BIIB
FY2019 $14.4B $60M 49.0% -906.8% BIIB
FY2020 $13.4B $800M 33.8% -95.0% BIIB
FY2021 $11.0B $18.5B 25.9% 72.0% MRNA
FY2022 $10.2B $19.3B 29.9% 48.9% MRNA
FY2023 $9.84B $6.85B 11.8% -61.9% BIIB
FY2024 $9.68B $3.24B 16.9% -121.9% BIIB
FY2025 $9.89B $1.94B 13.1% -158.1% BIIB

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BIIB (7) vs MRNA (3)
Institutional Metric BIIB MRNA Criterion Row Winner
Market Capitalization Scale $37.0B $93.6B Larger Scale MRNA
Trailing P/E Ratio Valuation 109.9x 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation 15.6x 23.0x Lower Multiple BIIB
Revenue Growth (YoY) Growth +10.6% +29.2% Higher Growth MRNA
Operating Margin (TTM) Profitability 23.5% -80.8% Higher Margin BIIB
Net Profit Margin Profitability 3.4% -110.5% Higher Margin BIIB
Return on Equity (ROE) Capital Efficiency 1.9% -34.5% Higher ROE BIIB
52-Week Range Position Momentum 92% ($160โ€“$261) 75% ($22โ€“$281) Stronger Trend BIIB
Beta / 30D Volatility Risk Regime 0.27ฮฒ ยท 36% Vol 2.35ฮฒ ยท 101% Vol Lower Realized Risk BIIB
Unified Institutional Score Composite Signal 50.2 / 100 (HOLD) 46.8 / 100 (HOLD) Higher Composite BIIB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BIIB vs MRNA Buy Guide
BIIB CONSOLIDATION
17d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live BIIB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
18d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BIIB nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.